Risk Factors for Sudden Cardiac Death or Unexplained Death in Patients Treated with Clozapine: A Systematic Review
BJPsych Open · 2026-06 · 12 (S1) · S39-S39
DOI: 10.1192/bjo.2026.11234 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift BJPsych Open, online erschienen am 30.06.2026. Verfasst von Tejas Easwar und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aims
Clozapine is the gold-standard treatment for treatment-resistant schizophrenia but carries serious cardiac risks, including sudden cardiac death (SCD). Specific risk factors for SCD in clozapine-treated patients remain poorly defined. Aims were to systematically identify and synthesise evidence on risk factors for SCD and sudden unexplained death (SUD) in clozapine-treated patients, to guide clinical monitoring.
Methods
We conducted a systematic review following PRISMA guidelines (PROSPERO: CRD420250646384). Five databases were searched from inception to 13 October 2025. Studies reporting SCD or SUD in clozapine-treated patients were included without restrictions on study design, demographics, or diagnosis. Two reviewers independently screened studies and extracted data. Quality was assessed using JBI checklists and ROBINS-E tools. Given study heterogeneity, we performed structured narrative synthesis.
Results
Twenty-one studies (1989–2023) were included, comprising 498 cases of SCD/SUD in clozapine-treated patients. Risk factors were grouped into four categories: treatment intensity (high doses 525 mg/day, rapid titration), drug interactions (valproate, benzodiazepines, polypharmacy), lifestyle factors (smoking, obesity, diabetes, substance use), and monitoring. Two patterns emerged: early inflammatory myocarditis (weeks 2–6) and late-onset cardiomyopathy (months–years).
Conclusion
Clozapine-associated SCD appears multifactorial. These findings suggest a role for gradual titration, avoidance of high-risk co-medications, baseline biomarker monitoring, and ongoing management of metabolic and cardiovascular risk factors. Increased multidisciplinary surveillance may help identify patients at higher risk and inform clinical decision-making in clozapine-treated patients.
Zitieren
APA
Easwar, T., Chari, D., Abdullah, S., Tollinton, H., & Mukaetova-Ladinska, E. (2026). Risk Factors for Sudden Cardiac Death or Unexplained Death in Patients Treated with Clozapine: A Systematic Review. BJPsych Open, 12(S1), S39-S39. https://doi.org/10.1192/bjo.2026.11234
Vancouver
Easwar T, Chari D, Abdullah S, Tollinton H, Mukaetova-Ladinska E. Risk Factors for Sudden Cardiac Death or Unexplained Death in Patients Treated with Clozapine: A Systematic Review. BJPsych Open. 2026;12(S1):S39-S39. doi:10.1192/bjo.2026.11234
BibTeX
@article{Easwar2026,
author = {Easwar, Tejas and Chari, Damodar and Abdullah, Shahbaz and Tollinton, Hugh and Mukaetova-Ladinska, Elizabeta},
title = {Risk Factors for Sudden Cardiac Death or Unexplained Death in Patients Treated with Clozapine: A Systematic Review},
journal = {BJPsych Open},
year = {2026},
volume = {12},
number = {S1},
pages = {S39--S39},
doi = {10.1192/bjo.2026.11234}
}
EUVIMED